Association of deep venous thrombosis with prothrombotic gene polymorphism identified in lung cancer cases

Molecular Biology Reports

Volumn 38, Issue 4, 2011, Pages 2395-2400

  Arslan, Sulhattin ^a   Manduz, Šinasi ^a   Epöztürk, Küršat ^a   Karahan, Oǧuz ^a   Akkurt, Ibrahim ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Gene; Lung cancer; Mutation; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; GLYCOPROTEIN IIIA; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; BETA3 INTEGRIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA EXTRACTION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PATHOGENESIS; GENETICS; LUNG TUMOR; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN THROMBOSIS;

FACTOR V; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTEGRIN BETA3; LUNG NEOPLASMS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; VENOUS THROMBOSIS;

EID: 79960944871     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0373-y     Document Type: Article

References (38)

1. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR (2004) Deep vein thrombosis and pulmonary embolism in two cohorts: The Longitudinal Investigation of Thromboembolism Etiology. Am J Med 117:19-25
2. Young GL, Fedulla PF (2008) Pulmonary thromboembolic disease. In: Fishman AP, Elias JA, Grippi MA, Kaiser LR, Senior RM (eds) Fishman's pulmonary diseases and disorders, 4th edn. McGraw-Hill, New York, pp 1423-1447
3. Johnson MJ, Spoule MW, Paul J (1999) The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol 11:105-110
4. Maxwell GL, Myers ER, Clarke-Pearson DL (2000) Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstet Gynecol 95:206-214
5. Ravin AJ, Edwards RP, Krohn MA, Kelley JR, Christopherson WA, Roberts JM (2002) The factor V Leiden mutation and risk of venous thromboembolism in gynecologic oncology patients. Obstet Gynecol 100:1285-1289
6. Mao C, Domenico DR, Kim K, Hanson DJ, Howard JM (1995) Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg 130:125-134
7. Sallah S, Wan JY, Nguyen NP (2002) Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87:575-579
8. Hastaoǧlu O, Sokullu O, Sanioǧlu S, Ş enay Ş , Akkan K, Er R, Bilgen F (2008) The relationship between deep venous thrombosis and undiagnosed malignant disease. Turk J Thorac Cardiovasc Surg 16(4):241-243
9. Rak J, Klement P, Yu J (2006) Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. Vnitr Lek 52(1):135-138
10. Scarvelis D, Wells PS (2006) Diagnosis and treatment of deepvein thrombosis. CMAJ 175(9):1087-1092
11. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma. Blood 88(10):3698-3703
12. Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 3:2471-2478
13. Nomori H, Nakajima T, Noguchi M, Shimasato Y (1991) Cytofluorometric analysis of metastases from lung adenocarcinoma with special reference to the difference between hematogenous and lymphatic metastases. Cancer 67:2941-2947
14. Rodenhuis S, Boerrigter L, Top B, Slebos RJ, Mooi WJ, van't Veer L, van Zandwijk N (1997) Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 15: 285-291
15. Ishihara S, Minato K, Hoshino H, Saito R, Hara F, Nakajima T, Mori M (1999) The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens. Lung Cancer 26:187-194
16. FalangaA,Rickles FR (1999) Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25:173-182
17. Morange PE, Henry M, Tregouët D, Granel B, Aillaud MF, Alessi MC et al (2000) The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 20:1387-1391
18. Dönmez Y, Kanadasi M, Tanriverdi K, Demir M, Demirtas M, Cayli M (2004) Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 45:505-512
19. Hendler MF, Meschengieser SS, Blaco AN, Alberto MF, Salviú MJ, Gennari L et al (2004) Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects. Am J Hematol 76:330-337
20. Castoldi E, Rosing J (2004) Factor V Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol 11:176-181
21. Curigliano G, Mandalà M, Sbanotto A, Colleoni M, Ferretti G, Bucciarelli P, Peruzzotti G, de Braud F, De Pas T, Spitaleri G, Pietri E, Orsi F, Banfi MG, Goldhirsch A (2006) Factor V Leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. Support Cancer Ther 3(2): 98-102
22. Hillarp A, Zöller B, Svensson JP, Dahlbäck B (1997) The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 78:990-992
23. Brown K, Luddington R, Williamson D, Baker P, Baglin T (1997) Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3'-untranslated region of the prothrombin gene. Br J Haematol 98:907-909
24. Gurgey A, Haznedaroglu IC, Egesel T, Buyukasik Y, Ozcebe OI, Sayinalp N, Dundar SV, Bayraktar Y (2001) Two common genetic thrombotic risk factors: factor V Leiden and prothrombin G20210A in adults Turkish patients with thrombosis. Am J Hematol 67(2):107-111
25. Frosst P, Blom HJ, Milos RP, Goyette CA, Sheppard RG, Matthews GJH, Boers M, den Heijer LAJ, Kluijtmans LP, van den Heuve RR (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113
26. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169-172
27. Hanson NQ, Aras O, Yang F, Tsai MY (2001) C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 47:661-666
28. Zheng YZ, Tong J, Do XP, Pu XQ, Zhou BT (2000) Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. Br J Haematol 109:870-874
29. Spiroski I, Kedev S, Antov S, Arsov T, Krstevska M, Dzhekova-Stojkova S, Bosilkova G, Kostovska S, Trajkov D, Petlichkovski A, Strezova A, Efinska-Mladenovska O, Spiroski M (2008) Methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genotypes and haplotypes and plasma homocysteine levels in patients with occlusive artery disease and deep venous thrombosis. Acta Biochim Pol 55(3):587-594
30. Akar N, Akar E, Akçay R, Avcu F, Yalç?n A, Cin S (2000) Effect of metylenetetrahydrofolate reductase 677 C-T, 1298 A-C, and 1317 T-C on factor V 1691 mutation in Turkish deep vein thrombosis patients. Thromb Res 97(3):163-167
31. Munhoz TP, Scheibe RM, Schmitt VM (2005) Angiotensin converting enzyme (ACE) DD genotype: relationship with venous thrombosis. Rev Bras Hematol Hemoter 27(2):87-90
32. Danser AH, Schalekamp M, Bax WA, van den Brink AM, Saxena PR, Riegger GAJ, Schunkert H (1995) Angiotensin-converting enzyme in the human heart. Effect of the Deletion/Insertion polymorphism. Circulation 92:1387-1388
33. Dilley A, Austin H, Hooper WC, Lally C, Ribeiro JA, Wenger NK, Rawlins P, Evatt B (1998) Relation of three genetic traits to venous thrombosis in an African-American population. Am J Epidemiol 147(1):30-35
34. Sperr WR, Huber K, Roden M, Janisiw M, Lang T, Graf S, Maurer G, Mayr WR, Panzer S (1998) Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. Thromb Res 90:117-123
35. Ridker PM, Hennekens CH, Schmitz C, Stampf MJ, Lindpaintner K (1997) PI A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet 349:385-388
36. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K (2005) Plasminogen activator inhibitor I (PAI-1) 4G/5G gene polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 36(8):1661-1665
37. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY (2001) 4G/5G polymorphism of the plasminogen activator inhibitor I gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 11:294-299
38. Song J, Yoon YM, Jung HJ, Hong SH, Park H, Kim JQ (2000) Plasminogen activator inhibitor-1 4G/5G promotor polymorfism and coagulation factor VII Arg353 Gln polymorfism in Korean patients with coronary artery disease. J Korean Med Sci 15: 146-152